简介：目的观察532激光在翼状胬肉术后应用的临床效果。方法将翼状胬肉术后1月结膜表现为Ⅱ、Ⅲ、Ⅳ级患者共72例97眼行532激光治疗。结果治疗前Ⅱ级35眼全部转变成Ⅰ级外观;治疗前Ⅲ级30眼转变成Ⅰ级10眼,转变成Ⅱ级15眼,无变化5眼;治疗前Ⅳ级32眼治疗后转变成Ⅲ级12眼,转变成Ⅱ级5眼,无变化15眼。结论激光治疗阻断新生血管,改善术后外观,对于Ⅱ、Ⅲ级患者降低了复发的风险,治疗效果显著,对于Ⅳ级患者抑制纤维增生,缓解了病情。

简介：目的分析Nd：YAG激光行后囊膜切开术治疗白内障复明手术后不同类型后发性白内障的治疗作用与术后并发症。方法对白内障复明手术后,109例（109眼）后发性白内障依据后囊昆浊形态分为：A组Elschnig珍珠样小体型46例（46眼）,B组纤维化型63例（63眼）。采用十字形切开法或开罐式切开法进行激光后囊膜切开术,比较两组激光术前最佳矫正视力与激光术后最佳矫正视力以及激光术后并发症情况。结果A、B两组内激光术后最佳矫正视力较激光术前最佳矫正视力改善（P〈0.05）;A组术后眼压升高和房水闪辉明显高于B组（P〈0.05）。结论Nd：YAG激光是治疗白内障复明手术后不同类型后发障的常用有效的治疗方法,激光术后并发症与后发性白内障类型有关。

简介：目的探讨Nd：YAG激光联合鼻腔内逆行植入鼻泪管支架治疗鼻泪管阻塞的临床疗效。方法使用Nd：YAG激光治疗机对鼻泪管阻塞部位进行疏通,然后行鼻腔内逆行植入鼻泪管支架。术后冲洗泪道,2个月后拔除支架。结果对28例（35眼）行激光泪道成形联合鼻腔内逆行植入鼻泪管支架。术后随访一年,治愈32眼占91.43%。结论Nd：YAG激光联合鼻腔内逆行植入鼻泪管支架治疗鼻泪管阻塞痛苦小,效果好。

简介：AIM:Toevaluatechangesintheanteriorchamberdepth(ACD),crystallinelensthickness(LT)anditsrefractivepowerafterlaserinsitukeratomileusis(LASIK).·METHODS:Inallcases,thepreoperativeandpostoperativecentralACDwhichweremeasuredwithPentacam,Orbscan,IOL-MasterandA-scanultrasonography,centralcornealtruenetpowerwhichwasmeasuredwiththePentacam,OrbscanandIOL-Master,axiallength(AL)whichwasmeasuredwithIOL-MasterandLTwhichwasmeasuredwiththeA-scanultrasonographywerecomparedusingthepairedsamplettest.OcularrefractiveerrorsandlensrefractivepoweratcornealplanewerecalculatedandtheircorrelationswerealsoevaluatedbeforeandafterLASIK.RESULTS:At1weekafterLASIK,LTandcrystallinelensrefractivepoweratcornealplane(Dlens)whichwereassociatedwiththeIOL-MasterandPentacamincreasedsignificantly(P≤0.005),ACDdecreasedsignificantly(P≤0.001),butnosignificantincreasewasobservedintheDlenswhichwasassociatedwiththeOrbscan(P=0.261).SignificantcorrelationsbetweenthechangesintheocularrefractiveerrorsandDlenswhichwereassociatedwiththePentacamwereobservedat1weekand6monthsafterLASIK(P=0.028;P=0.001).CONCLUSION:LTincreasedsignificantlyafterLASIK,andthismightpartiallyleadtoACDdecrease,Dlensincreaseandasmallquantityofmyopicregression.

简介：AIM:Tofindouttheoutcomeoflaserphotocoagulationinclinicallysignificantmacularedema(CSME)byopticalcoherencetomography(OCT).·METHODS:Itwasaprospective,non-controlled,caseseriesstudyenrolling81eyesof64patientswithCSMEbetweenAugust2008andJanuary2010.AllpatientsreceivedmodifiedgridphotocoagulationwithfrequencydoubledNd:YAGlaser.Eachpatientwasevaluatedintermsofbest-correctedvisualacuity(BCVA)andregressionorprogressionofmaculopathyafterlasertherapyat1,3and6months.Spearman’scorrelationtestwasusedtoshowthecorrelationbetweenBCVAandtotalmacularvolume(TMV).Analysisofvariance(ANOVA)wasusedtocompareamonggroupsandindependentt-testwasusedtocompareineachgroup.·RESULTS:ThereishighcorrelationbetweenBCVAandTMV(P≤0.001).BCVAimprovedin50.6%,remainedstaticin39.5%anddeterioratedin9.9%patientsafter6monthoftreatment.TheBaselineTMV(meanandSD)were9.26±1.83,10.4±2.38,11.5±3.05,8.89±0.75and9.47±1.98mm3fordifferentOCTpatterns,ST(spongelikethickening),CMO(cystoidmacularedema),SFD(subfovealdetachment),VMIA(Vitreomacularinterfaceabnormality)andaverageTMVrespectively(P=0.04).After6monthsoflasertreatment,themeanTMVdecreasedfrom9.47±1.98mm3to8.77±1.31mm3(P=0.01).InSTtherewassignificantdecreaseinTMV,P=0.01,Furtherwithinthesegroupsat6months,theyweresignificantlydifferent,P=0.01.·CONCLUSION:OCTshowedthedifferentmorphologicalvariantofCSMEwhiletheresponseoftreatmentisdifferent.TMVdecreasedthemostandhenceshowedtheimprovementinvisionafter6monthsoflasertreatment.IntheeraofAntivascularendothelialgrowthfactors(VEGFs),efficacyoflaserseemstobeinshadowbutitisstillfirstlineoftreatmentindevelopingnationlikeNepalwhereantiVEGFsmaynotbeeasilyavailableandaffordable.